The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies.
about
Monoclonal antibodies targeting CD38 in hematological malignancies and beyondMonoclonal antibodies in the treatment of multiple myeloma: current status and future perspectivesPotential role of daratumumab in the treatment of multiple myelomaInnovative agents in multiple myelomaMagic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meetingSmoldering multiple myeloma.Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma - a phase II trial.Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study.Molecular mechanism and functional role of brefeldin A-mediated ADP-ribosylation of CtBP1/BARS.Nicotinamide phosphoribosyltransferase in malignancy: a review.Antibody-modified T cells: CARs take the front seat for hematologic malignancies.Immunologic microenvironment and personalized treatment in multiple myeloma.Elotuzumab and daratumumab: emerging new monoclonal antibodies for multiple myeloma.Daratumumab and its potential in the treatment of multiple myeloma: overview of the preclinical and clinical development.Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?Role of the Immune Response in Disease Progression and Therapy in Multiple Myeloma.Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.Emerging antibodies for the treatment of multiple myeloma.Refractory IgD Multiple Myeloma Treated with Daratumumab: A Case Report and Literature Review.Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression.Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.Emerging drugs and combinations to treat multiple myeloma.Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma.Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab.Daratumumab: Dawn of a New Paradigm in Multiple Myeloma?Daratumumab for the Treatment of Multiple Myeloma.When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapyCD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
P2860
Q26766718-8D01BCC7-BF69-407E-81A9-2CAE1D6EDF54Q26799104-841AE8E0-2822-4A99-AEF9-BE0609B8C88FQ26824157-51E85130-CECB-4979-8072-CE9C08512ED8Q27022493-46EB9B91-370A-40E9-A5DA-92C6E35BD790Q28075816-4CA36F8F-9A71-4C7B-9298-504F19A6E82CQ28082855-4AC961ED-A8F6-42FF-BF0A-0856DF5D5523Q33434683-ADE53DAD-7FBF-4B09-A3AB-2CC80C737BE9Q33437691-6F0BFFAB-95BA-45DD-862E-077EE86B0B35Q33600826-DDE7633B-8C6A-4F2B-8673-B44C1BE276DEQ36932363-76702A1B-2DEA-4E5C-A1B0-D356FEDB3264Q37424391-A3C1299F-D63B-4DB7-BF3E-2A881DEA7088Q37723469-1FC188F3-D9DE-4CCE-B118-351809EDEA73Q38108390-C1FFB71E-498E-4B16-8D47-174E6DDF8C0AQ38139998-E198614F-7C52-4AB5-956B-62BAA341DA85Q38542091-9E841DEA-3A58-4455-931E-012505328DC5Q38737970-563C0893-1E6F-40E4-8363-E06055844A05Q38815399-C5B3C605-0594-4D79-B025-F594098AEF07Q38817467-C81EB01A-FAE9-4D38-9C08-A4DF1B69AC4AQ38838239-951C141C-C004-4C29-A6ED-D4B270881EE8Q38983458-D5FEDA10-62A8-4054-A7E2-7BEE2CF1558EQ39093915-F23FC6FF-AE1C-4D74-89FB-F12A17F3260DQ39341524-AF782BA4-A608-4BEF-AAD5-6014C582871DQ41694198-357A6CFE-086B-4EFB-8467-CD76F2259A06Q49539698-DDC1E0DF-C2B9-46CE-9507-0AE04752EAD0Q50138095-680A9996-0055-4610-B322-A16AFD9EA350Q53507006-31577B80-2E0E-48EA-8C93-55548418B7E4Q55021985-105C30D3-BB22-494D-AAC4-5072D03B8F32Q55337411-2401AE93-3D75-4BD9-B679-75B3BD4142E0Q56908507-BB382AB9-6D9A-4665-9576-C1F7A8F14C81Q57191729-0887FCD1-0500-4AA2-BD8B-72C6C850F912
P2860
The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
The therapeutic human CD38 ant ...... emerging multi-drug therapies.
@en
type
label
The therapeutic human CD38 ant ...... emerging multi-drug therapies.
@en
prefLabel
The therapeutic human CD38 ant ...... emerging multi-drug therapies.
@en
P2093
P2860
P356
P1433
P1476
The therapeutic human CD38 ant ...... emerging multi-drug therapies.
@en
P2093
B van Kessel
H M Lokhorst
J M Bakker
M S van der Veer
M de Weers
S Wittebol
P2860
P2888
P356
10.1038/BCJ.2011.42
P577
2011-10-28T00:00:00Z
P5875
P6179
1030606540